For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Dabigatran Approved for SPAF in the US
November 1, 2010
- Cabazitaxel Improves Survival in Prostate Cancer Patients
November 1, 2010
- Astellas Licenses Dysuria Drug from ASKA
November 1, 2010
- MSD Launches Higher-Strength Asmanex
November 1, 2010
- BI's Combination Drug for Hypertension Receives EU Approval
November 1, 2010
- Afinitor plus Sandostatin Extended PFS in NET Patients: Novartis
November 1, 2010
- Shionogi Allies with Swedish Academia
November 1, 2010
- CDFS Subcommittee to Discuss Safety Measures for Mylotarg
November 1, 2010
- Precaution Statements to Be Revised for Ketoprofen-Based OTC Drugs
November 1, 2010
- Takeda Sets Up Global Business Development Organization
November 1, 2010
- PMDA to Have Fewer Active Officials Dispatched from Korosho
November 1, 2010
- Daiichi Sankyo Healthcare Voluntarily Recalls Skin Cream
November 1, 2010
- Takara Bio Acquires Oncology Business from M's Science
November 1, 2010
- Daiichi Sankyo: Anti-Flu Drug Inavir
November 1, 2010
- The Pharma Gospel of Praise
November 1, 2010
- Nobelpharma Considers Independent Marketing of New Products
November 1, 2010
- Nichi-Iko Ties Up with Aprogen of South Korea for Biosimilars
November 1, 2010
- Fixed-Dose ARB/CCB Combinations Reduce ADRs: Prof. Hasebe
November 1, 2010
- Pfizer Acquires 40% Stake in Brazilian Generic Company
November 1, 2010
- Generics' Share in Japan Will Not Become as Large as in the West: Prof. Nakamura
November 1, 2010
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…